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Abstract. Background: Urinary tract infections account for ~30% of healthcare-associated infections reported
by hospitals. Virtually all healthcare-associated urinary tract infections (HAUTIs) are caused by instrumentation of
the urinary tract, creating an opportunity to prevent a large proportion of HAUTIs, including catheter-associated
urinary tract infections (CAUTIs). In Australia, there is no specific national strategy and surveillance system in
place to address HAUTIs or CAUTIs. To determine the need for prospective surveillance of HAUTIs, we propose
undertaking a national point prevalence study. This paper describes the methods that could be used to undertake
such a study.
Methods: A cross-sectional point prevalence design is proposed. The population is all patients hospitalised
overnight in Australian hospitals, with the sample to exclude outpatients and those in emergency departments. The
proposed operational definition is that used by the Health Protection Agency. A standardised training package for
data collectors is recommended with standardised data collection and analysis processes described. Individual
patient consent should be waived.
Discussion: Explanation of aspects of the proposed methods are provided, primarily based on findings from a
pilot study that informed the development of the proposed protocol. This included development and delivery of
training for data collectors and use of the Health Protection Agency HAUTI surveillance definition, rather than the
Centers for Disease Control definition.
Conclusion: Conducting a national point prevalence study on HAUTIs including CAUTIs will provide evidence
that can be subsequently used to debate the cost effectiveness and value of prospective surveillance. By conducting
a pilot study and critically evaluating that process, we have been able to propose a method that could be used for a
single hospital or national study.
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Background
Healthcare associated infections (HAIs) are a relatively
commonbut unintended consequence of receiving healthcare,
particularly in hospitals. The effects of HAIs are not only felt
by individual patients through increased morbidity and
mortality, but also by a health service through higher costs
associated with infections. The magnitude of the effect of
HAIs on patients is evidenced by several point prevalence
studies1–3 and a report from the World Health Organization.4
These studies suggest the prevalence ofHAIs in hospitals to be
~8%, with urinary tract infections (UTIs) being one of the
leading types of infection, accounting for ~30% of infections
reported by acute care hospitals.5 In addition, virtually all
healthcare-associated urinary tract infections (HAUTIs) are
caused by instrumentation of the urinary tract, with ~80%
traced to the use of an indwelling urinary catheter (catheter-
associated urinary tract infections or CAUTIs).6 This creates
an opportunity to prevent a large proportion of HAUTIs.
Calculation of how many CAUTIs may be preventable
varies considerably, with estimates from unpublished data
ranging from 17% to 69%.7 The first Australian national
prevalence survey for nosocomial and community-acquired
infections was conducted in 1984, with reports of a 6.3%
prevalence of HAIs and 22% of these infections being UTIs.8




More recently, an incidence of 1.66% forHAUTIs specifically
has been reported from twohospitals inQueensland.9A recent
point prevalence survey in the United States of America
reported a prevalence of 6.0% for HAIs, with 15.5% arising
from urinary tract infections.10
To date, in Australia there is no specific national strategy
and surveillance system in place to address HAUTIs and
CAUTIs.11 To determine the need for prospective
surveillance of HAUTIs, we proposed undertaking a
national point prevalence study. To provide a foundation
for this study and for future prospective interventional
studies, we conducted a preliminary study in six Australian
hospitals (three public and three private) in two Australian
States/Territories. In this pilot study, we examined not only
the prevalence of HAUTI and CAUTI, but also compared
two HAUTI surveillance definitions for their positive
predictive value and useability. These findings will be
published elsewhere. In addition, we evaluated our approach
to conducting a point prevalence study through reflection
and surveys of the research assistants who undertook this.
Through this process, we have proposed this protocol, to
provide a suitable methodological approach for conducting
prevalence surveys for HAUTIs in Australia.
A consistent methodology for conducting prevalence
surveys in Australia is required to facilitate hospitals
undertaking such a study and allow data to be collected in a
manner which permits comparison and aggregation. The
proposed protocol can be used by infection control personnel
to evaluate the burden of HAUTI in their hospital and
provides a framework for policy makers to determine the
feasibility of a national point prevalence study in this area.
In this paper we describe a suitable methodological approach




The aim for a study using this protocol is to determine the
point prevalence of HAUTIs in Australian hospitals.
Design
A cross-sectional study.
Study setting and participants (national)
All patients hospitalised in an overnight bed in an Australian
hospital. Units where the risk of UTI is deemed very low, for
example those with no catheter usage, such as mental health
units, can be excluded. Emergency department and outpatient
department patients may also be excluded as these fluctuating
numbers will greatly affect the calculation of denominators.
Outpatients and patients categorised as maintenance care




There are two methods that can be used to determine
whether a person has a UTI – a microbiological or non-
microbiological approach.1 A person has a UTI if they meet
the criteria for one or both of these approaches.1 Symptoms
used to define a case of microbiologically or non-
microbiologically confirmed UTI must be documented in
the medical or nursing notes. Verbal communication is not
acceptable. The definitions of both these approaches are
provided below and summarised in Fig. 1.
* A microbiologically confirmed UTI is when a patient has
at least one of the following signs or symptoms with no
other recognised cause: fever (>38C), urgency, frequency,
dysuria, or suprapubic tenderness and the patient has a
positive urine culture, that is,105microorganisms per mL
of urine with nomore than two species of microorganisms.1
* A non-microbiologically confirmed UTI is when a patient
has at least two of the following with no other recognised
cause: fever (>38C), urgency, frequency, dysuria, or
suprapubic tenderness and at least one of the following:
positive dipstick for leukocyte esterase and/or nitrate;
pyuria urine specimen with 10 WBC mL–1 or 3 WBC/
high-power field of unspun urine; organisms seen on Gram
stain of unspun urine; at least two urine cultures with
repeated isolation of the same uropathogen (Gram-
negative bacteria or S. saprophyticus) with  102 colonies
mL–1 urine in non-voided specimens; 105 colonies mL–1
of a single uropathogen (Gram-negative bacteria or
S. saprophyticus) in a patient being treated with effective
antimicrobial agent for a urinary infection; physician
diagnosis of a urinary tract infection; or physician institutes
appropriate therapy for a urinary infection.1 Bloodstream
infections secondary to asymptomatic bacteriuria are not
included in this definition.
A patient has a CAUTI if they meet the definition of a
having a UTI and if an indwelling catheter was in situ at
time of infection onset or removed in previous 48 h before
symptom onset.
A person with a UTI, including HAUTI, is defined as
‘healthcare associated’ when infection onset is on day 3 of
admission onwards (or greater than 48 h if this can be easily
identified). In addition, cases are healthcare associated if
infection onset occurs on day 1 or day 2 and patient was
Implications
* In Australia, there is no specific national strategy and
surveillance system in place to address urinary tract
infection surveillance
* A consistent methodology for a point prevalence
study on urinary tract infections is required
* We propose a method for that could be used for a
single hospital or national study
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discharged from a hospital in the preceding 48 h or if infection
onset was on day 1 or day 2 and patient has a relevant device
inserted on this admission before onset.1
Data items to be collected
For each patient, the following data items are to be
collected: date of survey, hospital, ward/location, sex, date
of birth, date of admission, whether the person has a HAUTI
and if so whether it was microbiologically or non-
microbiologically confirmed. For those persons with a UTI,
the symptoms should be recorded to assist with validation or
further analysis at a later date.
Training
Persons responsible for data collection (research assistants)
should be trained and assessed in their knowledge and
application of surveillance definitions. This is an essential set
in improving the reliability of study findings. A standardised
training package should be developed and be available for
use by participating hospitals. An assumption is that research
assistants will have a healthcare professional background.
Procedure
Data collectionwill occur on agiven day in all participating
hospitals. Research assistants will collect data on all in-
patients in each ward/unit in the hospital at the beginning of
the day from the hospital patient administration system or
equivalent. In larger hospitals or where there are insufficient
researchers to complete the survey on one day, there may be
queries regarding inclusion criteria or follow up of patients.
In such circumstances, the following principles are to be
applied:
* If patient notes are available to enable data collection after
the study day, this is permissible. The researcher must only
review data from the actual study day and the lead up. For
example, if the study occurred on 1 January, but the
researcher was unable to review the notes until 4 January,
the assistantwill be looking to determinewhether the person
had an infection on 1 January and cannot use information
available after this date.
* If the patient has been transferred to another ward during
data collection, every attempt should bemade to follow that
person up.
* If the patient was discharged on the study day, every attempt
should be made to review the notes of that patient and
include them in the study where possible.
* If the patient notes or laboratory results were unavailable
at the time of data collected, e.g. in theatre, an attempt
should be made to follow that person up.
* Where data are not available, that patient should not be
included in the calculation of prevalence. However, a
statement of limitation should be made about the number
of patients for which data are not available.
Fig. 2 summarises the procedure for determining cases of
HAUTI.
Data management and analysis
In clinical settings where Wi-Fi is available, an online data
collection form should be used for data entry. Alternatively,
data can be collected in a hard copy form and subsequently
entered into an online database. The online database should
be developed and managed by one organisation. Descriptive
analysis such as counts and percentages for categorical
data and measures of central tendency and dispersion for
Does this patient have a 
potential HAUTI? 
Microbiologically confirmed UTI 
Positive urine culture, that is, ≥ 105
microorganisms per mL with no more than 2 
species of microorganisms   
AND
One or more of the following: Fever 
(>38°C), urgency, frequency, dysuria, or 
suprapubic tenderness  
Non microbiologically confirmed UTI 
At least two of the following with no other recognized cause:  
• Fever (>38°C), urgency, frequency, dysuria, or suprapubic 
tenderness  
AND 
At least one of the following:   
• Positive dipstick for leukocyte and/or nitrate 
• Pyuria urine specimen with ≥ 10 WBC/mL or ≥ 3 WBC/high-
power field of unspun urine 
• Organisms seen on Gram stain of unspun urine 
• ≥ 2 urine cultures with repeated isolation of the same 
uropathogen, Gram-negative bacteria (or S. saprophyticus) 
with ≥ 102 colonies/mL urine in non voided specimens) 
• ≤105 colonies/mL of a single uropathogen (Gram-negative 
bacteria or S. saprophyticus) in a patient being treated with 
effective antimicrobial agent for a urinary infection  
• Physician diagnosis of a UTI 
• Physician institutes appropriate therapy for a UTI or 
suprapubic tenderness  
Fig. 1. Determining whether a participant has an HAUTI. Source: Health Protection Agency.1
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continuous data will be performed. The HAUTI and CAUTI
point prevalence will be calculated using the total eligible
patient population surveyed on the day (excluding patients
for whom data are not available) as the denominator.
Ethical considerations
Participating organisations may require ethics approval from
their Human Research Ethics Committee. Advice should be
sought locally. For organisations requiring ethics approval,
this research protocol can be used to assist in the process. No
individual patient will be contacted. Information is obtained
from laboratory results and from patient notes recorded as
part of their routine care. Consent from individual patients
will not be obtained. Section 2.3.1 of the National Statement
on Ethical Conduct outlines the principles for wavering
consent.12 To assist constructing an ethics application for
organisations that require ethics approval, we will now
provide some key principles for the justification for wavering
consent.
* The research is low risk. There are no interventions and no
harm or discomfort as a result.
* The benefits of the research justify any risk of harm
associated with not obtaining consent. No harm from not
obtaining consent is envisaged. Results of the research are
not individualised or indeed patient identifiable.
* There is no known or likely reason for thinking that
patients would not have consented if they had been asked.
The study requires no direct involvement of patients;
rather it collates existing information obtained during their
hospitalisation.
* The privacy and confidentiality of patients and patient data
will be maintained by ensuring that no re-identifiable
information will be stored or held by the researcher after
the conclusion of data collection and no re-identifiable
data will be passed onto the national database for analysis.
* Obtaining consent would also necessitate the researchers
having access to a greater level of personal information.
* No new information will be obtained about individual
patients; therefore results will have no significance for the
individual welfare of patients.
* The study will not result in depriving patients of any
financial benefits.
* The potential benefits to the public outweigh the risks or
harm associated with no obtaining consent. There are
~175 000 healthcare-associated infections (HAIs) in
Australian acute healthcare facilities per year, makingHAIs
Identify patients hospitalised in an overnight 
bed in an Australian hospital. 
Outpatients, patients in 
psychiatric units, patients 
categorised as maintenance 
care type and emergency 
departments 
Does the person have a UTI? 
Refer to Figure 1
Is the UTI HCA? 
Infection onset: 
Day 3 or > 48 hours after admission OR
Day 1 or Day 2 AND discharged in preceding 48 hours OR
Day 1 or day 2 AND has device inserted this admission prior to onset 
Is the UTI a CAUTI? 
Indwelling catheter insitu at time of infection onset or removed in 
previous 48 hours prior to symptom onset? 
Yes No 
CAUTI HAUTI 
End of review - 
move to next 
eligible patient 
No 
Review individual patients’ notes 
Exclude 
Fig. 2. Summary of data collection procedure.
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the most common complication affecting patients in
hospital.13
* Finally, obtaining patient consent would greatly increase
the time and cost of the surveillance.
Discussion
The focus of this discussion is in defence of the protocol
outlined in this paper. There were important lessons learnt
from the pilot study conducted in six Australian hospitals
informing this research protocol. The pilot study examined
the development and delivery of training for data collection,
an evaluation of different surveillance definitions, time taken
to collect data and the trial andmodificationof adata collection
instrument.
During the pilot of this research project, a training package
was developed for data collectors explaining all necessary
procedures. In developing this package, it was assumed that
all data collectors have some prior clinical and infection
control knowledge, for example registered nurses. The
training package was developed based on the Health
Protection Scotland Education and Training Events
resources.14 The package included a paper-based manual
and electronic presentation which took approximately 1 hour
to deliver. It wasmandatory for all data collectors to undertake
this training. The outcome of the training was evaluated by
post training case study assessments and participants were
allowed to proceed with data collection based on achieving a
minimum score of 80% in the assessments. Such a process
enhanced inter-rater reliability and we propose that any
national point prevalence study include the development and
delivery of a robust training package, conducted well before
the data collection day.During our pilot,we provided research
assistants with a manual and a one page surveillance
definition, as described in Fig. 1.
After completing our HAUTI point prevalence study in
Australian hospitals, 10 of the 11 research assistants (data
collectors) involved in the study completed an online
anonymous survey designed to gain valuable feedback for the
development of this protocol paper. Sixty-three per cent of
respondents indicated it took between 6 and 10 h per 100
patients to complete data collection. It is important to note,
however, that during the pilot additional information was
being collected, including an audit of all indwelling catheter
usage and documentation from a patient’s entire admission,
and that two different surveillance definitions to determine
the HAUTI status were being used. The research assistants
reported that the most time-consuming element of the data
collection process was reviewing patients’ notes to collect
informationoncatheter usage– something that is not proposed
in a national point prevalence study.
Sixty per cent of respondents suggested that it took
minimal time to determine the HAUTI and CAUTI status of
patients, whilst 20% indicated it took a long time. For most of
patients, the data collected suggested 40% of the time it
took less than 5min per patient to determine whether they
had a HAUTI or CAUTI. From the data collected and our
experience of the pilot, we estimate it would take ~3–6 h per
100 patients. This time would be reduced further with direct
online data entry at the point of data collection.
In our pilot study, we also evaluated the data collection
form used and the utility of two surveillance definitions,
namely the Health Protection Agency1 and Centers for
Disease Control and Prevention5 definitions. An evaluation
of the positive predictive value of the two surveillance
definitions is published elsewhere finding little difference.
However, in this paper, we report the evaluation of research
assistants (Table 1). These data, coupled with the positive
predictive value of the HPA surveillance definition, are the
main reasons why we have proposed the Health Protection
Agency surveillance definitions for use in the Australian
context, as summarised in Figs 1 and 2.
Communication is also a key element of conducting any
study, including a point prevalence study. In the hospitals
where we conducted the pilot, ward manager and senior
nurses were notified well in advance of the study date. In the
lead up to the study, reminders were sent and written
information about the study was available for interested staff.
We did not encounter any challenges by ward or clinical staff
in conducting our pilot.
Conclusion
Conducting a national point prevalence study on HAUTIs
including CAUTIs will provide evidence that can be
subsequently used to debate the cost effectiveness and value
in prospective surveillance. By conducting a pilot study and
critically evaluating that process, we have been able to
propose a method that could be used for any national point
prevalence study and or for individual hospitals to conduct
their own prevalence study.
Funding
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Table 1. Feedback on ease of use for different surveillance definitions (%, n= 10)
UTI, urinary tract infection; HPA, Health Protection Agency; CDC, Centers for Disease Control and Prevention
Definition and ease of use Very easy Easy Neither easy or hard Hard Very hard
CDC – symptomatic UTI definition 10 30 30 30 –
CDC – asymptomatic bacteraemia UTI definition 10 30 30 30 –
HPA – microbiological confirmed symptomatic UTI definition 10 60 30 – –
HPA – non-microbiological confirmed symptomatic UTI definition 10 60 30 – –
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